As a cyclo-oxygenase-2 inhibitor, parecoxinib was found to reduce OPN expression through blockade of the nuclear receptor subfamily 4 group A member 2 (NR4A2) and Wnt signalling pathways, in intestinal tumours of mice [101]. Here, NR4A2 is linked to intestinal neoplasm.